# Safety and Effect on Pain and Function According to RAPID-3 of IHL-675A in Patients With Rheumatoid Arthritis

> **NCT05942911** · PHASE2 · TERMINATED · sponsor: **Incannex Healthcare Ltd** · enrollment: 20 (actual)

## Conditions studied

- Rheumatoid Arthritis

## Interventions

- **DRUG:** IHL-675A
- **DRUG:** Cannabidiol
- **DRUG:** Hydroxychloroquine
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05942911
- **Lead sponsor:** Incannex Healthcare Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2023-11-22
- **Primary completion:** 2024-10-28
- **Final completion:** 2025-10-28
- **Target enrollment:** 20 (ACTUAL)
- **Why stopped:** Recruitment challenges
- **Last updated:** 2026-03-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05942911

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05942911, "Safety and Effect on Pain and Function According to RAPID-3 of IHL-675A in Patients With Rheumatoid Arthritis". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT05942911. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*